Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.42 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.42 |
| ▸ | PAK4 | O96013 | 4/20 | 0.38 |
| ▸ | TTBK1 | Q5TCY1 | 4/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12001630 | 0.92 | MAP3K14 (0.42) | MAP3K14PRKD1PAK4TTBK1CDC7 | |
| SCHEMBL12001727 | 0.87 | MAP3K14 (0.42) | MAP3K14PRKD1PAK4TTBK1CDC7 | |
| SCHEMBL12001741 | 0.86 | MAP3K14 (0.41) | MAP3K14PRKD1PAK4 | |
| SCHEMBL11970854 | 0.86 | PAK4 (0.56) | MAP3K14PRKD1PAK4 | |
| SCHEMBL12001509 | 0.84 | MAP3K14 (0.57) | MAP3K14PRKD1PAK4TTBK1CDC7 | |
| SCHEMBL12001579 | 0.83 | MAP3K14 (0.48) | MAP3K14PRKD1PAK4TTBK1CDC7 | |
| SCHEMBL12001798 | 0.82 | MAP3K14 (0.47) | MAP3K14PRKD1PAK4TTBK1CDC7 | |
| SCHEMBL12001718 | 0.82 | MAP3K14 (0.47) | MAP3K14PRKD1PAK4TTBK1CDC7 | |
| SCHEMBL12001580 | 0.80 | MAP3K14 (0.45) | MAP3K14PRKD1PAK4TTBK1CDC7 | |
| SCHEMBL12001724 | 0.79 | MAP3K14 (0.41) | MAP3K14PRKD1PAK4TTBK1CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | NFKB1, NFRKB, NFKBIA | MAP3K14 519/4885PRKD1 1505/4885PAK4 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.